Approval · Notice of Compliance 2300 · 2001
GLUCAGON: Notice of Compliance 2300
Issued January 11, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2300
- Date
- January 11, 2001
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Hyperglycemic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GLUCAGON | 02243297 | Cancelled Post Market |
Medicinal ingredients
- GLUCAGON (RECOMBINANT DNA ORIGIN) 1 MG per VIAL